Apontis Pharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Apontis Pharma's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 9% per year.
Belangrijke informatie
-48.7%
Groei van de winst
-59.4%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | -9.0% |
| Rendement op eigen vermogen | -22.9% |
| Nettomarge | -17.4% |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce
Oct 17Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?
Jun 18Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08Opbrengsten en kosten
Hoe Apontis Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 41 | -7 | 18 | 0 |
| 31 Mar 24 | 39 | -9 | 19 | 0 |
| 31 Dec 23 | 37 | -11 | 21 | 0 |
| 30 Sep 23 | 42 | -7 | 21 | 0 |
| 30 Jun 23 | 46 | -3 | 21 | 0 |
| 31 Mar 23 | 51 | 0 | 21 | 0 |
| 31 Dec 22 | 56 | 3 | 20 | 0 |
| 30 Sep 22 | 56 | 3 | 19 | 0 |
| 30 Jun 22 | 56 | 4 | 17 | 0 |
| 31 Mar 22 | 54 | 2 | 18 | 0 |
| 31 Dec 21 | 51 | -1 | 20 | 0 |
| 30 Sep 21 | 48 | -1 | 21 | 0 |
| 30 Jun 21 | 46 | -1 | 22 | 0 |
| 31 Mar 21 | 42 | -1 | 20 | 0 |
| 31 Dec 20 | 39 | -1 | 18 | 0 |
| 31 Dec 19 | 40 | -2 | 19 | 0 |
| 31 Dec 18 | 20 | 0 | 8 | 0 |
Kwaliteitswinsten: APPH is currently unprofitable.
Groeiende winstmarge: APPH is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: APPH is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Versnelling van de groei: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement op eigen vermogen
Hoge ROE: APPH has a negative Return on Equity (-22.86%), as it is currently unprofitable.